摘要
目的 以盐酸地尔硫上(艹)下(卓)普通片为参比制剂,研究盐酸地尔硫上(艹)下(卓)控释胶囊的药代动力学性质和相对生物利用度。方法 采用自身对照法,健康志愿受试者分别单剂量和多剂量口服盐酸地尔硫上(艹)下(卓)控释胶囊与普通片,采用反相高效液相色谱法测定地尔硫上(艹)下(卓)血药浓度变化情况,3P87药代动力学程序进行处理。结果 单剂量 po 60 mg盐酸地尔硫上(艹)下(卓)控释胶囊与普通片的AUCo→τ分别为(637.56±106.18) h·μg·L-1和(597.39±117.60) h·μg·L-1,tmax分别为(59.5±8.0)μg·L-1和(99.7±8.2) μg·L-1,tmax分别为(4.5±0.5) h和(3.0±0.3) h,t1/2分别为(5.9±1.1) h和(5.3±0.7) h,相对生物利用度为(106.39±12.53)%。多剂量 po 盐酸地尔硫上(艹)下(卓)控释胶囊(每次60 mg,每日2次)与盐酸地尔硫上(艹)下(卓)普通片每次30 mg,每日3次达稳态后,AUCo→τ分别为(620.35±73.75) h·μg·L-1和(303.90±54.53) h·μg·L-1,cssmax分别是(79.0±7.6)μg·L-1与(73.3±12.6) μg·L-1,cssmin分别是(33.1±5.5)μg·L-1与(23.9±5.7)μg·L-1,css分别为(51.7±6.2)μg·L-1和(38.0±6.8)μg·L-1,tmax分别为(3.4±0.5)h与(1.7±0.2) h,波动度(DF)分别是(0.89±0.11)与(1.30±0.16),相对生物利用度为(102.06±11.46)%。以配对 t 检验与双单侧 t 检验对上述参数进行统计分析,两种制剂的 AUC 无显著性差异(P>0.05),而其它参数均有显著性差异(P<0.05)。结论 两种制剂具生物等效性;盐酸地尔硫上(艹)下(卓)控释胶囊具有显著的控释特征。
Abstract
OBJECTIVE To study the pharmacokinetics and relative bioavailability of diltiazem hydrochloride controlled-release (DTZ-CR) capsule in healthy male volunteers.METHODS Diltiazem tablet was used as the refereace.A crossover self-control study of single and multiple dose was conducted on 12 healthy volunteers.Plasma concentrations were determined by HPLC.RESULTS The pharmacokinetic parameters after a single dose of 60 mg DTZ-CR capsule were: AUC0→τ=(637.56±106.18) h·μg·L-1,cmax=(59.5±8.0) μg·L-1,tmax(4.5±0.5) h,t1/2=(5.9±1.1) h,respectively.The relative bioavailability was (106.39±12.53)%.The degree of fluctuation for steady state of multipledoses was (0.89±0.11) μg·L-1,which were significantly lower than that of the reference tablet.CONCLUSION The two formulations were of bioequivalence and DTZ-CR capsule had marked characteristics of controlled release.
关键词
盐酸地尔硫上(艹)下(卓) /
药代动力学 /
相对生物利用度 /
高效液相色谱法
{{custom_keyword}} /
Key words
diltiazem /
pharmacokinetics /
bioavailability /
HPLC
{{custom_keyword}} /
何林 王建新 李铜铃 程强 李芚.
盐酸地尔硫上(艹)下(卓)控释胶囊的药代动力学和生物利用度[J]. 中国药学杂志, 2000, 35(09): 606-610
HE Lin;WNG Jin-xin;LI Tong-ling;CHENG Qing;LI Tun.
The pharmacokinetics and relative bioavailability of diltiazem hydrochloride controlled-release capsule in healthy volunteers[J]. Chinese Pharmaceutical Journal, 2000, 35(09): 606-610
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1]中国药典1995年版.二部[S],1995:600.
[2]刘晓东.缓释制剂生物利用度研究技术规范修订参考[J].中国临床药理学与治疗学杂志,1997,2(3):217.
[3]高连用,刘昌孝.FDA药物体内生物等效性指导原则介绍[J].中国临床药理学与治疗学杂志,1997,2(1):58.
{{custom_fnGroup.title_cn}}
脚注
{{custom_fn.content}}